FeesSafety
Pluang+

Palvella Therapeutics to unveil third QTORIN™ program in live webcast on Nov 19, 2026

Market News
19 Nov 2026, 00:00 WIB
GlobeNewsWire
View Source
Bullish
Palvella Therapeutics to unveil third QTORIN™ program in live webcast on Nov 19, 2026

Palvella Therapeutics, a clinical-stage biopharmaceutical company focused on rare skin diseases, will announce its third product candidate from the QTORIN™ platform in a live webcast on November 19, 2026. This new program expands Palvella's pipeline targeting serious, rare skin and vascular conditions with no FDA-approved treatments. The webcast will provide details on the new candidate and is accessible via the company's website, with a replay available for 90 days. This announcement highlights Palvella's ongoing commitment to developing novel therapies for underserved medical needs.

Palvella Therapeutics' new QTORIN™ program announcement is set against a Health-sector market where 49 of 150 US stocks rose and 100 fell on November 19, 2026. Among notable movers as of 04:02 WIB, UnitedHealth Group Inc (UNH) traded at USD 349.73 with a 1-day change of -10.25% and Pluang order activity showing 88% Sell / 12% Buy, while GeneDx Holdings Corp (WGS) rose 10.15% to USD 52.09 despite 99% Sell activity. Alumis Inc. (ALMS) declined 9.81% to USD 4.37, with a typical hold time of 21 days on Pluang.

More News

Alpha Tau Medical reports positive trial results ahead of earnings on Nov 19, 2026.

Alpha Tau Medical reports positive trial results ahead of earnings on Nov 19, 2026.

Alpha Tau Medical is set to report earnings on November 19, 2026, with expected losses of $0.15 per share and revenue of $125,000. The company announced positive clinical trial results from its U.S. REGAIN trial for Alpha DaRT therapy in glioblastoma...

Company Fundamentals
Bullish
53 minutes ago
Nvidia shares fall 2.9% despite strong earnings and raised revenue forecast amid leadership and regulatory concerns.

Nvidia shares fall 2.9% despite strong earnings and raised revenue forecast amid leadership and regulatory concerns.

Nvidia's stock dropped 2.9% to $150.96 after initially rising on strong quarterly results and a raised revenue forecast for fiscal 2028, projecting 75% annual growth. However, investor concerns about leadership uncertainty, including calls for former...

Neutral
1 hour ago
B&G Foods raises full-year sales and EBITDA guidance on strong volume growth and debt reduction plans

B&G Foods raises full-year sales and EBITDA guidance on strong volume growth and debt reduction plans

B&G Foods increased its full-year net sales and adjusted EBITDA guidance following a 5% volume-driven sales growth in Q3 2026. The company is expanding beyond traditional retail into food service, clubs, and private labels to utilize factory capacity...

Company Fundamentals
Bullish
1 hour ago
CoreWeave shares drop 4.13% amid strong AI demand but investor worries over debt and financing costs.

CoreWeave shares drop 4.13% amid strong AI demand but investor worries over debt and financing costs.

CoreWeave's stock fell 4.13% despite strong AI demand and Nvidia's solid earnings, as investors focus on the company's heavy debt and financing challenges. The company reported 168% revenue growth and raised its 2026 revenue forecast to $13-$13.3 bil...

Bearish
1 hour ago
Performance Food Group posts 5.5% sales growth, targets $125M procurement savings by 2028

Performance Food Group posts 5.5% sales growth, targets $125M procurement savings by 2028

Performance Food Group reported a 5.5% net sales increase in fiscal Q1 2027, driven by growth in independent restaurant orders and expanding gross profit margins. The company aims to achieve $125 million in annual procurement savings by fiscal 2028 t...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App